AIM: To evaluate therapeutic effects of histaglobin drugs (histaglobin and histaglobin-triplex) in patients with continuous allergic rhinitis (CAR) and chronic recurrent (idiopathic) urticaria (CRU). MATERIALS AND METHODS: The drugs were given to 45 patients with CAR and high sensitivity to household allergens confirmed by cutaneous diagnostic tests or high IgE level, and 40 patients with CRU with typical cutaneous lesions. The drugs were injected subcutaneously (a total of 6 injections, 2 ml of solution each) with the interval 2-3 or 3-4 days. Histaglobin was given as 12 mg of normal human immunoglobulin + 0.00015 mg of histamine dihydrochloride. Histamine-triplex as 36 mg of immunoglobulin + 0.00045 mg of histamine dihydrochloride. The treatment was repeated in a months (3 injections). Clinical response was assessed in scores by the scale of clinical symptoms. RESULTS: Histaglobin relieved symptoms of CAR (from 7.34 +/- 0.095 to 1.7 +/- 0.04 scores on the treatment day 28, p < 0.01). After the repeated course CAR symptoms attenuated to 1.6 +/- 0.057 scores). Extranasal symptoms significantly reduced too. Excellent and good results were achieved in 80% of the patients. Positive results were also obtained in 82.5% of CRU patients. Tolerance of histaglobin and histaglobin-triplex was good. CONCLUSION: In the tested regimen, both histaglobin and histaglobin-triplex proved effective in CAR and CRU when routine treatment failed.
AIM: To evaluate therapeutic effects of histaglobin drugs (histaglobin and histaglobin-triplex) in patients with continuous allergic rhinitis (CAR) and chronic recurrent (idiopathic) urticaria (CRU). MATERIALS AND METHODS: The drugs were given to 45 patients with CAR and high sensitivity to household allergens confirmed by cutaneous diagnostic tests or high IgE level, and 40 patients with CRU with typical cutaneous lesions. The drugs were injected subcutaneously (a total of 6 injections, 2 ml of solution each) with the interval 2-3 or 3-4 days. Histaglobin was given as 12 mg of normal human immunoglobulin + 0.00015 mg of histamine dihydrochloride. Histamine-triplex as 36 mg of immunoglobulin + 0.00045 mg of histamine dihydrochloride. The treatment was repeated in a months (3 injections). Clinical response was assessed in scores by the scale of clinical symptoms. RESULTS: Histaglobin relieved symptoms of CAR (from 7.34 +/- 0.095 to 1.7 +/- 0.04 scores on the treatment day 28, p < 0.01). After the repeated course CAR symptoms attenuated to 1.6 +/- 0.057 scores). Extranasal symptoms significantly reduced too. Excellent and good results were achieved in 80% of the patients. Positive results were also obtained in 82.5% of CRU patients. Tolerance of histaglobin and histaglobin-triplex was good. CONCLUSION: In the tested regimen, both histaglobin and histaglobin-triplex proved effective in CAR and CRU when routine treatment failed.